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G
TSAs the public continues to cry out to “wage the war on
ancer,”34 identifying genomic profiles that predict progno-
is, and using molecular marker assays to predict therapeu-
ic response, developing clinically relevant studies for more
elective therapies will become increasingly important. In-
egrating molecular testing and chemotherapy resistance
ssays into future adjuvant chemotherapy trials for NSCLC
ill facilitate avoiding yet another decade of pure empiri-
ism in patient care. This paradigm shift appears necessary
nd justified.
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r David M. Jablons (San Francisco, Calif). It is a pleasure to
eview this paper. I have only a few questions and some observa-
ions.
What we have heard here this morning, or at least what is in the
anuscript, is a retrospective analysis of a large, prospectively gath-
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TSred sample of patients with early-stage resected NSCLC for the
urpose of assaying in a primary cell culture system—remember, on
gar—chemotherapy resistance, not sensitivity. It is an impressive
xperience over many years. More than 4500 fresh tumor samples
ere submitted to a commercial entity, Oncotech, Inc, which is a
or-profit organization, for chemoresistance testing and ultimately
ecently gene analysis. This a reimbursable test currently that has
ained some but not universal acceptance. An important distinc-
ion was brought up in the talk and needs to be reinforced: these
ssays are chemoresistance and not chemosensitivity, and as such
he authors argue are more “credible” and more predictive of
linical response. It may be that they are right, but certainly no
ssessment can be made from the dataset presented today. I would
gree to a certain extent that a tritium proliferation assay in a
ong-term culture of 5 days on agar is perhaps more quantifiable
nd may be more accurate. Perhaps the advantage of having a
rude tumor preparation where you have a lack of tumor cell
solation and you have no macrodissection or microdissection can
ither be a good or a bad approach, in my opinion. It is good in the
ense that it is more representative of the actual tumor perhaps in
ts milieu with stromal cells and vascular cells and immune cells
nd maybe the purported cancer stem cells. Yet it may be that the
ack of tumor cell isolation allows or accounts for why this high
hemoresistance is observed. Remember that these cells are being
ultured, as I understood from the paper, in very high supraphysi-
logic concentrations of chemotoxic agents, 10-fold to 100-fold
igher, which are at least 2 to 3 log orders higher than they would
ver see in the microenvironment in vivo. So one quick question
hat comes to mind is, did these resistance patterns vary at all with
istology? For instance, there is no comment in the paper that there
as an association with adenocarcinoma versus squamous, subsets
f adenocarcinomas that we know are notoriously more chemore-
istant—for example, neuroendocrine, large cell, bronchoalveolar.
as there any attempt at Oncotech or otherwise to classify that?
lso, in the molecular analysis, was there any microdissection of
he tumors, because without that there is no way to safely contend
r conclude that what you are measuring is really tumor focus.
inally, what was the FedEx factor in this? We have all done these
xperiments and sent our samples, and I am curious there is no
omment as to the overall success rate. Having been in the gene
accine business for a long time, we were surprised that we could
et 80% viability shipping tumor samples for fresh autologous
accines across country, so how was it in this? Finally, how
ealistic is this assay? The answer, in my opinion, is not very.
espite the many objections and the artifactual-ness of the assay,
t has been shown as represented in the paper in several other
umor systems, ovarian and breast cancer, to have some prognostic
ctivity and validity. So I would ask the authors, who are busy
linicians and have a large thoracic surgery and lung cancer
ractice—this has not been validated prospectively and needs to
e, I agree—what have you been doing either off study or on study
n small pilot studies in your institution to validate this? Do you
se this as a proponent of this therapy, because it is highly
ontroversial in this assay? Do you personally use it to guide
herapy? If not, why not?
In the interest of time, I will limit the comments regarding stage
B adjuvant chemotherapy. I think it can be safely concluded now,
nd Eric is in the back and can concur, at ASCO just a few weeks a
62 The Journal of Thoracic and Cardiovascular Surgery ● Febrgo the analysis of the CALGB data is now a negative trial. The
arger trials and more robust longer follow-up trials, ANITA,
ALT, and others, showed no benefit for adjuvant platinum-based
hemotherapy in patients with stage 1B disease that are node
egative. So I no longer believe that is standard of care. There are
any issues with the molecular analysis of p53. It is only one
ene. It is notoriously inaccurate by immunohistochemistry. And
14, MDM2, there are lots of way to skin that gene, and when you
ust look for immunohistochemistry, it is very unpredictable and
nreliable.
In light of the impending revolution in molecular classification
nd fingerprinting of tumors and emergence of novel targeted
herapies and agents, just keep in mind that there are nearly 300
ew agents, not to mention Irv [Dr Irving Weismann]’s 300-odd
ompanies I’m sure, that are coming into clinical testing in the next
to 5 years. Is there a role in this day and age for the “old world”
hemotherapy and a reason to believe that in vitro chemoresistance
esting can be useful to select efficacious agents? Molecular anal-
sis is sexy and exciting and is, remember, mostly prognostic at
his point, but not therapeutic. So in the next 3 to 5 years, perhaps
onger, chemotoxic, cytotoxic chemotherapy is here to stay.
s such, anything, if validated prospectively, that can direct
nselected empiric therapy to select patient populations and their
umors would be a meaningful advance. As the saying goes, in the
and of the blind, the one eye is king. The time is ripe to test this
nd other in vitro chemoresistance assays for clinical response and
urvival as their end points. This is yet to be done in NSCLC.
It is time to put the assay to the real “test” road and design an
djuvant trial for the intergroup that has drug selection based on
ome form of rational in vitro testing as a basis, and only then can
e determine whether this is a valid approach.
Dr d’Amato. Thank you, Dr Jablons. I’ll try to address as
any of your questions as I can.
Currently, it is difficult to get many of the medical oncologists
o treat patients based on this assay. We do have several at the
niversity of Pittsburgh who will, and when I was in practice in
outhern California, I had several who would treat people based on
he assay. I put forward a proposal to the CALGB last year to use
he assay as a validation trial, as a single arm, nontreatment trial
hat would serve to validate the assay. The problem with an
ssay-directed versus empiric trial obviously is that that would
reate a subset of patients in whom you would eliminate plat-
num. Because that has been the standard of care for NSCLC,
liminating a platinum agent if a patient were resistant would be
eyond that, so a clinical validation, at least for the resectable
isease, is important. Those proposals are being put forth to the
ntergroup.
Regarding the assay and the mechanics of the assay, some-
here between 75% and 85%, what we call a valuability,
eaning viable tumor cells that can be cultured, arrived by
edEx when the tumors were prepared properly and sent and
id not sit on a loading dock. There are extremes from that, I’m
ure, as you have seen in your own experience with the vaccine
ork.
Stromal cells and vascular endothelial cells are inhibited in the
ssay conditions on agarose and this has been well established for
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TSow to culture tumor cells in the older (clonagenic) assays, so I
on’t believe that right now is a particular issue.
There are some differences between the frequencies of in vitro
esistance to chemotherapeutic agents in non–small cell tumor
ultures of different histology. For example, as we may expect
rom clinical observations, NSCLC tumors having bronchoalveo-
ar histology appear to exhibit more in vitro resistance to most
gents. These data are currently being analyzed and have yet to be
alidated. n
The Journal of ThoracicRegarding micro dissection, this is not performed for standard
mmunohistochemistry.
I believe that the molecular markers that we have chosen are
ifficult to assess in terms of the resistance assay. I also agree that the
mmunohistochemistry as end point measurements are not as accu-
ate, particularly with EGFR. The missing link here with these mark-
rs is the clinical data. Finding associations is interesting, but are they
eaningful? As you have noted, in the manuscript they probably areot meaningful in this context without clinical validation.
and Cardiovascular Surgery ● Volume 133, Number 2 363
